摘要
目的 论抗凝血酶III检测在血液透析患者中的应用。方法 随机选择我院需要血液透析的患者50例，设为观察组，选取50例健康体检者为对照组，应用全自动凝血分析仪迈瑞3510测定抗凝血酶（AT）活性（发色底物法），记录结果，得出结论。结果 检测之后观察组AT活性值低于对照组，差异有统计学意义（P＜0.05）。结论 使用本研究方法进行检测，除了诊断抗凝功能外，还有助于判断血液透析时肝素的抗凝效果，值得临床应用。
关键词： 临床应用；抗凝血酶；血液透析
Abstract
Objective ApplicATion of antithrombin III detection in hemodialysis pATients. Methods 50 pATients who need hemodialysis in our hospital were randomly selected as the observATion group, and 50 healthy people were selected as the control group.Determination of antithrombin (at) activity by Automatic Coagulation Analyzer Mindray 3510 (chromogenic substrate method), and the results were recorded to draw a conclusion. Results After the test, the AT activity in the observATion group was lower than thAT in the control group, with a stATistically significant difference (P<0.05). Conclusion Using this research method to detect, in addition to diagnosing the anticoagulATion function, it is also helpful to judge the anticoagulATion effect of heparin during hemodialysis, which is worthy of clinical applicATion.
Key words： Clinical applicATion; Antithrombin; Hemodialysis
参考文献 References
[1] PATel MS,Davies MG,Nassar GM,et al.Open repair and venous inflow plicATion (orvip)of the arteriovenous fistula(avf)is effective in treATing vascular steal syndrome.Ann Vacu Surg,2015,15(3):150-158.
[2] 陆明晰,冯剑,蒋欣欣,等.超声引导下经皮腔内血管成形术治疗血液透析患者动静脉内瘘狭窄.中华肾脏病杂志,2015,28(1):63-64.
[3] 史佳佳,马媛.观察连续性肾脏替代治疗尿毒症合并心力衰竭患者的检测干预[J].中西医结合心血管病杂志,2015,3(30):182-183.
[4] 芦泽源,王锋,汪年松.抗凝血酶III与肾损伤的相关研究进展[J].中国中西医结合肾病杂志,2015,16(6):549-550.
[5] Zhou XS，Qiao YF，Wu RP，et al．Study on relATed indexes of the coagulATion and fibrinolytic system after renal ischemia reperfusion injury in Wistar rATs[J]．Saudi Med，2016，34(6):579－583．
[6] 张曙晴,张骆军,李洪彬,等. 血液小而密低密度脂蛋白胆固醇、抗凝血酶III水平及血小板参数检测在2型糖尿病肾病中的应用价值研究[J]. 现代检验医学杂志,2021,036(002):70-74,97.
[7] 蓝唯. 抗凝血酶-III检测在慢性肾小球肾炎与泌尿系感染中的意义探究[J]. 中国保健营养,2019,029(020):325.
[8] 张宇,徐云雷,刘连清. 抗凝血酶III与CRP联合PCT在脓毒症诊断中的应用价值[J]. 国际检验医学杂志,2019,040(023):2905-2908,2911.
[9] 兰莎,罗涛,罗时勇.枸橼酸钠抗凝在高危出血危险患者血液透析治疗中的应用[J].透析与人工器官,2022,33(01):14-17.